Severe attenuation of the B cell immune response in Msh2-deficient mice.

Authors:
Vora KA; Tumas-Brundage KM; Lentz VM; Cranston A; Fishel R and 1 more

Journal:
J Exp Med

Publication Year: 1999

PMCID:
PMC2192912

PMID:
9927509

View on PubMed View on PMC
Journal Information

Full Title: J Exp Med

Abbreviation: J Exp Med

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Allergy and Immunology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Addendum: Resolvins suppress tumor growth and enhance cancer therapy.
Sulciner ML; Serhan CN; Gilligan MM and 18 more (2024) - Transparency Score: 2/6
Anti-PD-1 therapy triggers Tfh cell-dependent IL-4 release to boost CD8 T cell responses in tumor-d…
Ruggiu M; Guérin MV; Corre B and 9 more (2024) - Transparency Score: 3/6
Higher COVID-19 pneumonia risk associated with anti-IFN-α than with anti-IFN-ω auto-Abs in children.
Bastard P; Gervais A; Taniguchi M and 87 more (2024) - Transparency Score: 3/6
PROTAC-mediated NR4A1 degradation as a novel strategy for cancer immunotherapy.
Wang L; Xiao Y; Luo Y and 19 more (2024) - Transparency Score: 5/6
The effector program of human CD8 T cells supports tissue remodeling.
Delacher M; Schmidleithner L; Simon M and 32 more (2024) - Transparency Score: 4/6
View All Papers from This Journal
Transparency Score
1/6
0.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
COI Disclosure
Evidence found in paper:

"This work was supported by National Institutes of Health grants AI23739 to T. Manser, and CA56542 and CA67007 to R. Fishel. V.M. Lentz and K.A. Vora were supported by National Institutes of Health training grants AI07492 and CA09678, respectively."

Protocol Registration
Open Access
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025